CT9 Stock Overview
A clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cardiol Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.31 |
| 52 Week High | CA$2.80 |
| 52 Week Low | CA$0.73 |
| Beta | 0.59 |
| 1 Month Change | -10.00% |
| 3 Month Change | -35.27% |
| 1 Year Change | 67.39% |
| 3 Year Change | -23.60% |
| 5 Year Change | n/a |
| Change since IPO | -35.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| CT9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -2.5% | -2.6% |
| 1Y | 67.4% | -15.6% | 6.9% |
Return vs Industry: CT9 exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: CT9 exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| CT9 volatility | |
|---|---|
| CT9 Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CT9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CT9's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Elsley | www.cardiolrx.com |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
Cardiol Therapeutics Inc. Fundamentals Summary
| CT9 fundamental statistics | |
|---|---|
| Market cap | €101.77m |
| Earnings (TTM) | -€24.10m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.2x
P/E RatioIs CT9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CT9 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$36.14m |
| Earnings | -CA$36.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CT9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:06 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cardiol Therapeutics Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Nash | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Christian Orquera | First Berlin Equity Research GmbH |